The global pollen allergy market is experiencing an unprecedented surge, with demand skyrocketing to USD 5850.8 Million in 2023, according to recent market analysis. This remarkable growth trajectory is projected to continue at a Compound Annual Growth Rate (CAGR) of 4.2% in the forthcoming years, driven by technological innovations in healthcare.
The rise in pollen allergies, particularly hay fever, has led to an escalating prevalence of these conditions worldwide. This surge is further compounded by an increase in affected children, highlighting the pressing need for solutions within the global pollen allergy industry.
Technological advancements in healthcare are poised to revolutionize the landscape of pollen allergy treatment and management. With continuous research and development efforts, the market is anticipated to expand exponentially, reaching an estimated value of USD 8828.6 Million by 2033.
Get your Sample Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-16236
A significant driver behind this surge is rapid urbanization, particularly in advancing countries. As urban populations continue to grow, so does exposure to environmental allergens, consequently boosting the demand for pollen allergy management and treatment solutions.
The global pollen allergy market’s anticipated growth presents a substantial opportunity for stakeholders, including pharmaceutical companies, healthcare providers, and research institutions, to develop innovative approaches to address the escalating prevalence of pollen allergies worldwide.
Key Takeaways from the Market Study:
- As of 2023, the pollen allergy industry was valued at USD 5850.8 Million
- From 2023 to 2033, the pollen allergy industry is poised to grow at a 4.2% CAGR
- By 2033, the pollen allergy industry is slated to reach a valuation of USD 8828.6 Million
- Based on therapeutic drug class, Corticosteroids dominated the pollen allergy industry in 2023 with a revenue share of 35.5%.
- China is poised to yield a CAGR of 3.8% with respect pollen allergy in 2033
“Technological advancement in healthcare and increase in the prevalence of allergic rhinitis and rise in the number of patients especially children suffering from pollen allergies expected to radically transform the pollen allergy industry in the coming years,” comments an analyst at FMI.
Customization Available Upon Request: https://www.futuremarketinsights.com/customization-available/rep-gb-16236
Competitive Landscape:
Some of the leading manufacturers and players assessed in the global pollen allergy industry are
- bioMerieux SA
- HOB Biotech Group Corp Ltd
- Alcon
- HYCOR Biomedical, Inc
- Immunomic Therapeutics
- Quest Diagnostics Incorporated
- Omega Diagnostics Group PLC
- Siemens Healthcare Private Limited
- Stallergenes Greer
- Lincoln Diagnostics, Inc.
Manufacturers and players functional in the global pollen allergy industry are adopting various corporate growth strategies such as new product launches, mergers and acquisitions, and geographical expansion, among others.
- In July 2022 – Stallergenes Greer, a global healthcare company specialising in allergen immunotherapy (AIT), today announced positive data from its EfficAPSI real-world study. Presented at the 2022 European Academy of Allergy and Clinical Immunology (EAACI) congress in Prague (Czech Republic), the real-world study confirmed significant benefit of sublingual liquid allergen immunotherapy treatment (AIT) on the onset and worsening of asthma in patients with allergic rhinitis.
- Lincoln Diagnostics offers a painless option for skin allergy testing with the Multi-Test PC (pain control). This test still provides high sensitivity, high specificity, and low variability in results but with virtually no pain.
A Full Report on Market: https://www.futuremarketinsights.com/checkout/16236
Key Segments Covered in the Pollen Allergy Industry Survey:
Pollen allergy industry by Product Type:
- Instruments
- Consumables
- Services
Pollen allergy industry by Allergen Type:
- Food
- Inhaled
- Drug
- Other
Pollen allergy industry by Therapeutics Drug class:
- Antihistamines
- Decongestants
- Corticosteroids
- Mast Cell Stabilizers
- Leukotriene Inhibitors
- Nasal Anticholinergics
- Immunomodulators
- Auto injectable Epinephrine
- Immunotherapy
Pollen allergy industry by End-User:
- Diagnostic Laboratories
- Hospitals
Pollen allergy industry by Region:
- North America Pollen allergy industry
- Latin America Pollen allergy industry
- Europe Pollen allergy industry
- South Asia Pollen allergy industry
- East Asia Pollen allergy industry
- Oceania Pollen allergy industry
- MEA Pollen allergy industry
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube